New biologics for Crohn's: do they work? study reveals clues
NCT ID NCT04923100
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from China looked at 50 adults with Crohn's disease who were treated with two newer biologic drugs, Ustekinumab and Vedolizumab. The goal was to see how well these drugs control the disease and what factors might predict a good response. By analyzing past medical records, researchers hope to find clues that help doctors choose the right treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ustekinumab and Vedolizumab
- What this could lead to
- If successful, this could help doctors better predict which Crohn's patients will benefit most from these newer biologics.
- What could go wrong
- This is a small, observational study (50 people) that looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 501655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?